公司资料
Prothena 股价、新闻与催化剂
- 股票代码:
- PRTA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Ireland
股票表现
9.39 USD (-0.63%)
收盘价
最后更新: 2026年8月24日
481M USD
市值
股价为何变动
As of Aug 24, 2026, PRTA closed down 0.63% at $9.39. No new same-company headline was identified in the current news window.
公司概览
业务概览
Prothena is a neuroscience and protein-dysregulation biotechnology company focused on rare neurodegenerative and amyloid-related diseases. Its pipeline is aimed at high-unmet-need areas where clinical data can quickly change the market’s view.
所在地与行业分类
Headquartered in Ireland and listed on NASDAQ, Prothena has a transatlantic biotech profile. It sits in neuroscience and protein-misfolding biology.
商业模式特征
The company’s value is driven by clinical readouts, partnership activity, and the ability to translate deep biology into differentiated programs. Investors watch safety, efficacy, and the durability of its lead scientific hypotheses.
生物医药行业定位
Prothena sits in the high-risk, high-catalyst neuroscience niche of biotech. The stock can move sharply around data because the programs are small in number but potentially large in impact.
未来催化剂
- Prothena's catalysts are PRX012 and the tau/amyloid program cadence, with any next clinical update helping decide whether the neuroscience story still has real optionality. The market wants human data that can support a longer development path rather than another broad platform pitch.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。